Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Athena Neurosciences

Executive Summary

Licensing agreement with Sandoz gives firm U.S. and Canadian rights to tizanidine, a treatment for spasticity associated with multiple sclerosis, cerebral palsy, stroke, spinal cord injury and acute muscle spasm. Athena expects to begin U.S. Phase III trials and submit NDAs by the end of 1991 and 1992, respectively. Sandoz, which introduced tizanidine (Sirdalud) in West Germany in 1985 and Japan in 1988, will supply the finished product. South San Francisco-based Athena is negotiating two similar agreements as part of its plan to build a sales force in anticipation of marketing CNS drugs now under development.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel